Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Jakob Robert Izbicki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6807-8224; OpenAlex author ID A5039983309, A5109329116. Sources: ClinicalTrials.gov.

Their work

Papers
70 (first author 1, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
160
Papers, trials and grants by year

2011: 5 papers · 2012: 4 papers · 2013: 2 papers · 2014: 9 papers, 1 trial · 2015: 3 papers · 2016: 4 papers · 2017: 2 papers · 2018: 2 papers · 2019: 6 papers · 2020: 2 papers · 2021: 11 papers · 2022: 4 papers · 2023: 8 papers · 2024: 3 papers · 2025: 5 papers

Papers 50 of 70

  1. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  2. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  3. Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.35443↗
  4. Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08979-z↗
  5. Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03262-x↗
  6. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  7. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  8. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  9. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  10. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  11. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  12. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05728-y↗
  13. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  14. Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/clinchem/hvac214↗
  15. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  16. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  17. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  18. Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma. Co-author DOI 10.1177/03946320221106504↗
  19. Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/biomedicines10112955↗
  20. Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers14184405↗
  21. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  22. Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness. Co-author DOI 10.1080/07357907.2021.1943747↗
  23. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  24. Truncated O-GalNAc glycans impact on fundamental signaling pathways in pancreatic cancer. Co-author DOI 10.1093/glycob/cwab088↗
  25. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  26. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  27. Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression. Co-author DOI 10.1186/s13046-021-01946-2↗
  28. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  29. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  30. Evaluation of the Hamburg-Glasgow Classification in Pancreatic Cancer: Preoperative Staging by Combining Disseminated Tumor Load and Systemic Inflammation. Co-author DOI 10.3390/cancers13235942↗
  31. DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness. Co-author DOI 10.7717/peerj.11905↗
  32. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. Co-author DOI 10.1002/ijc.32567↗
  33. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  34. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  35. Oligometastases in pancreatic cancer (Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic o… First author DOI 10.1002/ags3.12255↗
  36. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  37. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  38. Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort. Co-author DOI 10.1016/j.ejso.2018.12.012↗
  39. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  40. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  41. Kidney Transplantation after Extended Multivisceral Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2018/3757382↗
  42. HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer. Co-author DOI 10.1007/s10495-016-1332-4↗
  43. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-lab… Co-author DOI 10.1016/s0140-6736(16)32409-6↗
  44. Pancreatic cancer and liver metastases: state of the art. Co-author DOI 10.1007/s13304-016-0407-7↗
  45. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicent… Co-author DOI 10.1016/j.surg.2016.02.019↗
  46. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv387↗
  47. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  48. Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry. Co-author DOI 10.1002/jso.23826↗
  49. Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? Co-author DOI 10.1007/s00268-014-2808-4↗
  50. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0386-1↗

Trials 1

  1. Neoadjuvant Treatment in Resectable Pancreatic Cancer Principal investigator NCT01900327↗

Closest collaborators

The 25 strongest of 160 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Faik Güntac Uzunoglu · 13 shared papers, 2014–2025 · strength 1.57
  2. Marianne Sinn · 7 shared papers, 2022–2025 · strength 1.10
  3. Maximilian Bockhorn · 24 shared papers, 2011–2021 · strength 1.09
  4. Cenap Güngör · 11 shared papers, 2011–2025 · strength 0.88
  5. Harriet Wikman · 5 shared papers, 2022–2025 · strength 0.81
  6. Christine Nitschke · 5 shared papers, 2022–2025 · strength 0.81
  7. Thilo Hackert · 6 shared papers, 2016–2025 · strength 0.66
  8. Florian Gebauer · 14 shared papers, 2011–2021 · strength 0.63
  9. Michael Tachezy · 13 shared papers, 2011–2021 · strength 0.60
  10. Yogesh Kumar Vashist · 14 shared papers, 2011–2018 · strength 0.57
  11. Leonie Konczalla · 4 shared papers, 2020–2025 · strength 0.51
  12. John P. Neoptolemos · 8 shared papers, 2014–2023 · strength 0.46
  13. Joseph Tintelnot · 3 shared papers, 2023–2025 · strength 0.43
  14. Michael Fabian Nentwich · 5 shared papers, 2012–2019 · strength 0.35
  15. Matthias Reeh · 5 shared papers, 2011–2021 · strength 0.34
  16. Gerrit Wolters‐Eisfeld · 5 shared papers, 2014–2021 · strength 0.31
  17. Till Krech · 3 shared papers, 2021–2022 · strength 0.31
  18. Till Sebastian Clauditz · 3 shared papers, 2021–2022 · strength 0.31
  19. Udo Schumacher · 5 shared papers, 2013–2021 · strength 0.31
  20. Danmei Zhang · 2 shared papers, 2023–2025 · strength 0.29
  21. Nicola Gagliani · 2 shared papers, 2023–2025 · strength 0.29
  22. Marija Trajkovic‐Arsic · 2 shared papers, 2023–2025 · strength 0.29
  23. Jens Thomas Siveke · 2 shared papers, 2023–2025 · strength 0.29
  24. Alec C. Kimmelman · 2 shared papers, 2023–2025 · strength 0.29
  25. Stefan Hubert Boeck · 2 shared papers, 2023–2025 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.